Intravitreal triamcinolone with photodynamic therapy for subfoveal choroidal neovascularisation in age related macular degeneration

British Journal of Ophthalmology

Volumn 88, Issue 3, 2004, Pages 344-347

  Rechtman, E ^a,b   Danis, R P ^a,c   Pratt, L M ^a   Harris, A ^a  

^a INDIANA UNIVERSITY   (United States)

^b KAPLAN MEDICAL CENTER   (Israel)

^c UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BENZOPORPHYRIN DERIVATIVE; TRIAMCINOLONE ACETONIDE;

AGED; CATARACT; DISEASE EXACERBATION; DRUG EFFECT; FEMALE; FOLLOW UP; HUMAN; INTRAOCULAR PRESSURE ABNORMALITY; MALE; PHOTODYNAMIC THERAPY; PRIORITY JOURNAL; RETINA MACULA AGE RELATED DEGENERATION; RETROSPECTIVE STUDY; REVIEW; SIDE EFFECT; SUBRETINAL NEOVASCULARIZATION; VISION;

AGED; AGED, 80 AND OVER; CHOROID; FEMALE; FOLLOW-UP STUDIES; GLUCOCORTICOIDS; HUMANS; INJECTIONS; MACULAR DEGENERATION; MALE; NEOVASCULARIZATION, PATHOLOGIC; PHOTOCHEMOTHERAPY; RETROSPECTIVE STUDIES; TRIAMCINOLONE ACETONIDE;

EID: 1542407176     PISSN: 00071161     EISSN: None     Source Type: Journal    
DOI: 10.1136/bjo.2003.027177     Document Type: Review

References (19)

1. Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: one-year results of 2 randomized clinical trials - TAP report. Treatment of age-related macular degeneration with photodynamic therapy (TAP) Study Group. Arch Ophthalmol 1999;117:1329-45.
2. Bressler NM. Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: two-year results of 2 randomized clinical trials-TAP report 2. Arch Ophthalmol 2001;119:198-207.
3. Verteporfin therapy of subfoveal choroidal neovascularization in age-related macular degeneration: two-year results of a randomized clinical trial including lesions with occult with no classic choroidal neovascularization - verteporfin in photodynamic therapy report 2. Am J Ophthalmol 2001;131:541-60.
4. Verteporfin therapy of subfoveal choroidal neovascularization in patients with age-related macular degeneration Additional information regarding baseline lesion composition's impact on vision outcomes. TAP Report No. 3. Arch Ophthalmol 2002;120:1443-54.
5. Argon laser photocoagulation for neovascular maculopathy. Five-year results from randomized clinical trials. Macular Photocoagulation Study Group. Arch Ophthalmol 1991;109:1109-14.
6. Laser photocoagulation of subfoveal neovascular lesions of age-related macular degeneration. Updated findings from two clinical trials. Macular Photocoagulation Study Group. Arch Ophthalmol 1993;111:1200-9.
7. Ronson NT, Danis RP, Ciulla TA, et al. Intravitreal triamcinolone in subfoveal recurrence of choroidal neovascularisation after laser treatment in macular degeneration. Br J Ophthalmol 2002;86:527-9.
8. Ciullo TA, Criswell MH, Danis RP, et al. Intravitreal triamcinolone acetonide inhibits choroidal neovascularization in a laser-treated rat model. Arch Ophthalmol 2001;199:399-404.
9. Danis RP, Bingaman DP, Yang Y, et al. Inhibition of preretinal and optic nerve head neovascularization in pigs by intravitreal triamcinolone acetonide. Ophthalmology 1996;103:2099-104.
10. Tano Y, Chandler D, Machemer R. Treatment of intraocular proliferation with intravitreal injection of triamcinolone acetonide. Am J Ophthalmol 1980;90:810-16.
11. Antoszyk AN, Gottlieb JL, Machemer R, et al. The effects of intravitreal triamcinolone acetonide on experimental pre-retinal neovascularization. Graefes Arch Clin Exp Ophthalmol 1993;231:34-40.
12. Folkmon J, Ingber DE. Angiostatic steroids. Method of discovery and mechanism of action. Ann Surg 1987;206:374-83.
13. Danis RP, Ciulla TA, Pratt LM, et al. Intravitreal triamcinolone acetonide in exudative age-related macular degeneration. Retina 2000;20:244-50.
14. Penfold PL, Gyory JF, Hunyor AB, et al. Exudative macular degeneration and intravitreal triamcinolone. A pilot study. Aust N Z J Ophthalmol 1995;23:293-8.
15. Challa JK, Gillies MC, Penfold PL, et al. Exudative macular degeneration and intravitreal triamcinolone: 18 month follow up. Aust N Z J Ophthalmol 1998;26:277-81.
16. Gillies MC, Simpson JM, Luo W, et al. A randomized clinical trial of a single dose of intravitreal triamcinolone acetonide for neovascular age-related macular degeneration: one-year results. Arch Ophthalmol 2003;121:667-73.
17. Jonas JB, Kreissig I, Hugger P, et al. Intravitreal triamcinolone acetonide for exudative age related macular degeneration. Br J Ophthalmol 2003;87:462-8.
18. Bakri SJ, Beer PM, Singh RJ, et al. Pharmacokinetics of intravitreal triamcinolone acetonide. [Abstract]. America Academy of Ophthalmology 2002:157.
19. Wingate RJ, Beaumont PE. Intravitreal triamcinolone and elevated intraocular pressure. Aust N Z J Ophthalmol 1999;27:431-2.